UroGen Pharma (URGN) Cash from Investing Activities (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Cash from Investing Activities data on file, last reported at -$20.7 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 20.32% year-over-year to -$20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.8 million (up 211.21% YoY) and the FY2025 annual result came in at $61.6 million, up 398.64% from the prior year.
• Cash from Investing Activities slipped to -$20.7 million in Q1 2026, from $27.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $60.6 million in Q4 2024 to a low of -$106.8 million in Q3 2024.
• A 5-year average of $1.2 million and a median of $6.3 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 2563.58% — and 2024, when it slumped 26720.95%.
• Tracing URGN's Cash from Investing Activities over 5 years: stood at $23.1 million in 2022, then plunged by 149.09% to -$11.3 million in 2023, then jumped by 634.39% to $60.6 million in 2024, then plunged by 54.28% to $27.7 million in 2025, then tumbled by 174.64% to -$20.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$20.7 million (Q1 2026), $27.7 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.